North America Next-generation Antibody Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Therapeutic Area (Oncology, and Autoimmune or Inflammatory) and Technology (Antibody-drug conjugates, Bispecific antibodies, Fc engineered antibodies, Antibody fragments & antibody-like proteins, and Biosimilar antibody products)
The North America next-generation antibody market is expected to reach US$ 5,428.80 million by 2028 from US$ 2,457.09 million in 2021. It is estimated to grow at a CAGR of 12.0% from 2021 to 2028.
The growth of the market is due to are increasing prevalence of cancer and growing demand for next-generation antibody therapeutics. However, complications associated with the manufacturing and approvals of next-generation antibodies is expected to restrict the market growth during the forecast period.
Cancer has emerged as a leading cause of death worldwide. According to the World Health Organization (WHO), cancer was the first leading cause of death in people below 70 years in 183 countries and the fourth leading cause of death in 123 countries worldwide in 2019. The rising prevalence of cancer has created a burden on the healthcare systems across the world. According to the International Agency for Research on Cancer (IARC), the global burden of new cancer cases is estimated to reach ~27.5 million by 2040. The disease is likely to cause ~163 million deaths by that year. Factors, such as lifestyle changes, smoking, reduced physical activities, and uncertain health and climatic conditions, are expected to increase the burden of cancer patients in several parts of the world in the coming years. Therefore, it is essential to control the increasing number of cancer patients worldwide.
Various governments have initiated programs and initiatives to increase the preventive measures and treatment for cancers. For instance, in 2017, World Health Assembly approved the Resolution Cancer (WHA70.12)—an integrated approach to prevent and control cancer. The program has been appealing to the WHO and various governments to accelerate their efforts to achieve the targets that are specified in the Global Action Plan (2013–2020) for the prevention and control of noncommunicable diseases (NCDs) and the 2030 UN Agenda for Sustainable Development to reduce early deaths from cancer. In addition, various private organizations have joined the action plans to prevent the increasing burden of cancer, creating a demand for better preventive measures against the disease. Thus, the rising prevalence of cancer has accelerated the need for new and effective therapeutic approaches, such as next-generation antibodies, boosting the market.
North America is highly affected due to the outbreak of the COVID-19 pandemic. The US-registered highest number of deaths due to the COVID-19 pandemic. The outbreak has put an immense burden on healthcare infrastructure in the US, Canada, and Mexico. Most pharmaceutical and biotechnological companies and research institutes are involved in developing COVID-19 vaccines and drugs.
Both established pharmaceutical companies and small startups have come forward to advance treatments and vaccines that target the infection created by the novel coronavirus. As a result, vaccine-related research activities in pharmaceutical and biotechnology companies, research centers, and educational research institutes are acknowledged essential and have been primarily unaffected in operations and output. However, due to the rise in research activities, the accessibility of funding for analysis and the need for antibodies, including next-generation antibodies, is anticipated to grow over the next few years.
Many researchers worldwide are involved in the viral examination of SARS-CoV-2, which develops COVID-19. Antibodies generated for both vaccines and therapeutics are examined to counterbalance the target virus for their functional efficiency.
The approval of monoclonal antibody services has increased for the development of COVID-19 vaccines. Companies engaging in the next-generation antibody market witnessed a negative impact on their services in early 2020 due to the temporary shutdown of their laboratories. However, as lockdown limitations were gradually lifted, research laboratories worldwide started reopening. As a result, most service providers prioritized actions to promote the critical work, such as giving a range of high-quality COVID-19-related research tools, reassigning R&D resources for producing essential products for SARS-Cov-2, expanding the supply chain, and supporting the augmented demand for long-term products required for SARS-CoV-2/COVID-19 research. They also focused on entering into discussions and collaborations concentrated on SARS-CoV-2 diagnostics, drugs, and vaccines development across the UK, the US, and China. Considering these factors, it can be declared that the impact of COVID-19 on the next-generation antibody market has been positive. Therefore, the COVID-19 pandemic is expected to aid the North America next-generation antibody market during the forecast period.
North America Next-generation Antibody Market Revenue and Forecast to 2028 (US$ Mn)
Get more information on this report :
NORTH AMERICA NEXT-GENERATION ANTIBODY MARKET SEGMENTATION
By Therapeutic Area
- Oncology
- Autoimmune/Inflammatory
By Technology
- Antibody-Drug Conjugates (ADC's)
- Bispecific Antibodies
- FC Engineered Antibodies
- Antibody Fragments and Antibody-like Proteins
- Biosimilar Antibody Products
By Country
- US
- Canada
- Mexico
Company Profiles
- F. HOFFMANN-LA ROCHE LTD.
- Kyowa Kirin Co., Ltd.
- Seagen Inc.
- ImmunoGen, Inc.
- Takeda Pharmaceutical Company Limited
- Amgen Inc.
- Pfizer Inc.
- Catalent Inc
- AstraZeneca
- Xencor
1. Introduction
1.1 Study Scope
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Next-generation Antibody Market – By Therapeutic Area
1.3.2 North America Next-generation Antibody Market – By Technology
1.3.3 North America Next-generation Antibody Market – By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Next-generation Antibody Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America PEST Analysis
4.3 Experts Opinion
5. Next-generation Antibody Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Prevalence of Cancer
5.1.2 Growing Demand for Next-Generation Antibody Therapeutics
5.2 Market Restraints
5.2.1 Complications Associated with Manufacturing and Approvals
5.3 Future Trends
5.3.1 Developments in Next-Generation Antibodies
5.4 Impact Analysis
6. Next-generation Antibody Market–North America Analysis
6.1 North America Next-generation Antibody Market Revenue Forecast and Analysis
7. North America Next-generation Antibody Market Revenue and Forecasts To 2028– by Therapeutic Area
7.1 Overview
7.2 North America Next-generation Antibody Market, By Therapeutic Area, 2021 & 2028 (%)
7.3 Oncology
7.3.1 Overview
7.3.2 Oncology: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
7.4 Autoimmune or Inflammatory
7.4.1 Overview
7.4.2 Autoimmune or Inflammatory: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
8. Next-generation Antibody Market Revenue and Forecasts To 2028 – Technology
8.1 Overview
8.2 Global Next-generation Antibody Market Share by Segment - 2021 & 2028 (%)
8.3 Antibody-drug conjugates
8.3.1 Overview
8.3.2 Antibody-drug conjugates: Next-generation Antibody Market Revenue and Forecast to 2028 (US$ Million)
8.4 Bispecific antibodies
8.4.1 Overview
8.4.2 Bispecific antibodies: Next-generation Antibody Market Revenue and Forecast to 2028 (US$ Million)
8.5 Fc engineered antibodies
8.5.1 Overview
8.5.2 Fc engineered antibodies: Next-generation Antibody Market Revenue and Forecast to 2028 (US$ Million)
8.6 Antibody fragments and antibody-like proteins
8.6.1 Overview
8.6.2 Antibody fragments and antibody-like proteins: Next-generation Antibody Market Revenue and Forecast to 2028 (US$ Million)
8.7 Biosimilar antibody products
8.7.1 Overview
8.7.2 Biosimilar antibody products: Next-generation Antibody Market Revenue and Forecast to 2028 (US$ Million)
9. North America Next-generation Antibody Market Revenue and Forecasts to 2028 – Country Analysis
9.1 North America: Next-generation Antibody Market
9.1.1 Overview
9.1.2 North America: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
9.1.3 North America: Next-generation Antibody Market, by Therapeutic Area, 2019–2028 (US$ Million)
9.1.4 North America: Next-generation Antibody Market, by Technology, 2019–2028 (US$ Million)
9.1.5 North America: Next-generation Antibody Market, by Country, 2021 & 2028 (%)
9.1.5.1 US: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
9.1.5.1.1 Overview
9.1.5.1.2 US: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
9.1.5.1.3 US: Next-generation Antibody Market, by Therapeutic Area, 2019–2028 (US$ Million)
9.1.5.1.4 US: Next-generation Antibody Market, by Technology, 2019–2028 (US$ Million)
9.1.5.2 Canada: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
9.1.5.2.1 Overview
9.1.5.2.2 Canada: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
9.1.5.2.3 Canada: Next-generation Antibody Market, by Therapeutic Area, 2019–2028 (US$ Million)
9.1.5.2.4 Canada: Next-generation Antibody Market, by Technology, 2019–2028 (US$ Million)
9.1.5.3 Mexico: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
9.1.5.3.1 Overview
9.1.5.3.2 Mexico: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
9.1.5.3.3 Mexico: Next-generation Antibody Market, by Therapeutic Area, 2019–2028 (US$ Million)
9.1.5.3.4 Mexico: Next-generation Antibody Market, by Technology, 2019–2028 (US$ Million)
10. Impact Of COVID-19 Pandemic on Next-generation Antibody Market
10.1 North America: Impact Assessment of COVID-19 Pandemic
11. Next-generation Antibody Market–Industry Landscape
11.1 Overview
11.2 Organic Developments
11.2.1 Overview
11.3 Inorganic Developments
11.3.1 Overview
12. Company Profiles
12.1 F. HOFFMANN-LA ROCHE LTD.
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Kyowa Kirin Co., Ltd.
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Seagen Inc.
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 ImmunoGen, Inc.
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Takeda Pharmaceutical Company Limited
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Amgen Inc.
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Pfizer Inc.
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Catalent Inc
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 AstraZeneca
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 Xencor
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms
LIST OF TABLES
Table 1. New Cancer Cases Registered Worldwide, 2020
Table 2. North America Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)
Table 3. North America Next-generation Antibody Market, by Technology– Revenue and Forecast to 2028 (US$ Million)
Table 4. US Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)
Table 5. US Next-generation Antibody Market, by Technology– Revenue and Forecast to 2028 (US$ Million)
Table 6. Canada: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)
Table 7. Canada Next-generation Antibody Market, by Technology– Revenue and Forecast to 2028 (US$ Million)
Table 8. Mexico: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)
Table 9. Mexico Next-generation Antibody Market, by Technology– Revenue and Forecast to 2028 (US$ Million)
Table 10. Organic Developments in the Next-generation Antibody Market
Table 11. Inorganic Developments in the Next-generation Antibody Market
Table 12. Glossary of Terms
LIST OF FIGURES
Figure 1. Next-generation Antibody Market Segmentation
Figure 2. Next-generation Antibody Market, By Country
Figure 3. North America Next-generation Antibody Market Overview
Figure 4. Oncology Segment Held Largest Share of Therapeutic Area Segment in Next-generation Antibody Market
Figure 5. North America Next-generation Antibody Market- Leading Country Markets (US$ Million)
Figure 6. North America: PEST Analysis
Figure 7. Experts Opinion
Figure 8. Next-Generation Antibody Market Impact Analysis of Driver and Restraints
Figure 9. North America Next-generation Antibody Market– Revenue Forecast and Analysis – 2021 - 2028
Figure 10. North America Next-generation Antibody Market, by Therapeutic Area, 2021 & 2028 (%)
Figure 11. Oncology: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
Figure 12. Autoimmune or Inflammatory: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
Figure 13. Global Next-generation Antibody Market Share by Segment - 2021 & 2028 (%)
Figure 14. Antibody-drug conjugates: Next-generation Antibody Market Revenue and Forecasts To 2028 (US$ Million)
Figure 15. Bispecific antibodies: Next-generation Antibody Market Revenue and Forecasts To 2028 (US$ Million)
Figure 16. Fc engineered antibodies: Next-generation Antibody Market Revenue and Forecasts To 2028 (US$ Million)
Figure 17. Antibody fragments and antibody-like proteins: Next-generation Antibody Market Revenue and Forecasts To 2028 (US$ Million)
Figure 18. Biosimilar antibody products: Next-generation Antibody Market Revenue and Forecasts To 2028 (US$ Million)
Figure 19. North America: Next-generation Antibody Market, by Key Country – Revenue (2021) (US$ Million)
Figure 20. North America Next-generation Antibody Market Revenue and Forecast to 2028 (US$ Million)
Figure 21. North America: Next-generation Antibody Market, by Country, 2021 & 2028 (%)
Figure 22. US: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
Figure 23. Canada: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
Figure 24. Mexico: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. Impact of COVID-19 Pandemic in North American Country Markets
- F. HOFFMANN-LA ROCHE LTD.
- Kyowa Kirin Co., Ltd.
- Seagen Inc.
- ImmunoGen, Inc.
- Takeda Pharmaceutical Company Limited
- Amgen Inc.
- Pfizer Inc.
- Catalent Inc
- AstraZeneca
- Xencor
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America next-generation antibody market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the North America next-generation antibody market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.